Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 1–24 of 157
Biological age clocks derived from DNA methylation patterns show significant day-to-day fluctuations within individuals, independent of actual chronological aging. This instability raises critical questions about their reliability for clinical application and longevity intervention assessment.
Epigenetic aging clocks measure chemical changes to DNA to estimate biological age, but they are research tools designed for population-level study, not reliable for individual health assessment. Consumer products marketing these tests as personal health indicators misrepresent their validity and clinical utility.
A digital twin technology modeling immune system dynamics in real time enables predictive health outcomes rather than reactive assessment. This shift from static testing to continuous simulation represents a substantive advance in personalized longevity medicine.
GlycanAge is hosting a conference with Mayo Clinic to advance clinical applications of glycan-based inflammaging markers, which can detect disease risk patterns up to a decade before symptomatic onset. The event aims to integrate chronic-inflammation testing into routine clinical practice.
Commercially available biological age tests based on epigenetic markers lack clinical validity, standardized accuracy measures, and actionable clinical utility. When physicians recommend them, they abandon evidence-based practice in favor of customer satisfaction, potentially replacing genuine health assessment with unfounded reassurance or unnecessary anxiety.
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Longitudinal changes in epigenetic clocks—molecular markers of biological age—independently predict mortality over 24 years, independent of baseline biological age. This establishes that the rate of epigenetic change itself, not just absolute age status, carries clinically actionable information for longevity assessment.
Hone Health integrated clinical-grade DEXA scans into its personalized longevity platform, enabling physicians to assess body composition changes—muscle, fat, and bone density—alongside metabolic and hormonal data. This shift from reactive screening to proactive monitoring allows earlier detection of metabolic drift and interventions before functional decline.
Hone Health integrated BodySpec DEXA scanning into its longevity platform, enabling real-time body composition, bone density, and metabolic rate assessment within clinical care plans. This shift moves bone health screening from reactive post-65 assessment to proactive longitudinal tracking across younger populations.
Superpower has integrated Galleri, a multi-cancer early detection blood test, into its preventative health platform. Data from PATHFINDER 2 showed that adding Galleri to standard screening increased cancer detection more than seven-fold, with over half of detected cancers identified at stage I or II.
Researchers developed OMICmAge, a DNA-methylation-based biological aging clock integrating proteomic and metabolomic data from 31,000 electronic medical records. The measure predicts mortality and age-related disease risk with performance comparable to or superior to existing biomarkers, offering a scalable tool for quantifying biological aging status.
Epigenetic age acceleration—measured through DNA methylation patterns—independently predicts cancer incidence in older adults, even after accounting for chronological age and established risk factors. This biomarker offers a quantifiable proxy for biological aging that may identify individuals at elevated cancer risk before conventional screening protocols would.
Aging clocks are biomarkers that quantify biological age independent of chronological time, offering a measurable framework to evaluate whether interventions actually slow aging. Their clinical utility depends on validating what they measure, understanding their mechanisms, and establishing whether changes in these markers correlate with meaningful health outcomes.
OMICmAge integrates multi-omics data with DNA methylation to create a biological age measure that predicts disease and mortality risk more accurately than chronological age alone. This approach enables risk stratification based on measurable molecular signatures rather than calendar years.
DeepStrataAge, a deep-learning model trained on DNA methylation patterns, identifies distinct aging trajectories between biological sexes and developmental stages, revealing that aging acceleration is not uniform across the lifespan. This sex- and stage-specific resolution improves the precision of biological age assessment and may refine risk stratification for age-related disease prevention.
SpectraCell's Baseline Nexus bundles four diagnostic tests—micronutrient status, lipoprotein particle profiling, telomere length, and MTHFR genotyping—into a single assessment designed to identify subclinical dysfunction before it progresses to clinical disease. The package reframes preventive diagnostics by measuring intracellular nutrient utilization and biological aging markers alongside conventional cardiovascular risk factors, enabling earlier intervention at the stage where metabolic and inflammatory processes are still modifiable.
SpectraCell introduced Baseline Nexus, a comprehensive assessment measuring intracellular micronutrient status, lipoprotein profiles, telomere length, and genetic variants through metabolically active lymphocytes rather than serum analytes alone. The test targets early detection of functional cellular deficits that compromise immune function and metabolic capacity—both determinants of health trajectory and aging rate.
DeepRare, a multi-agent AI system combining large language models with specialized diagnostic tools, demonstrated superior performance in identifying rare diseases compared to other digital tools and human physicians. The system addresses a critical clinical problem: patients with rare diseases wait an average of 5+ years for diagnosis, enduring repeated misdiagnoses and unnecessary interventions.
Sava Technologies has demonstrated a minimally invasive microsensor that continuously monitors glucose for 10 days with accuracy comparable to traditional continuous glucose monitors, while requiring a filament roughly 10 times shorter and causing substantially less tissue disruption. This advance addresses a critical adoption barrier in glucose monitoring, where discomfort and skin irritation have limited consistent use despite established clinical benefits.
Researchers developed a 14-protein aging clock from circulating extracellular matrix proteins that predicts biological age, distinguishes healthy from diseased states, and responds to rejuvenation interventions. This identifies ECM remodeling as a measurable biomarker and potential therapeutic target for age-related decline.
Organ-specific aging clocks that integrate multiple molecular data types—genomics, epigenomics, transcriptomics, proteomics, and metabolomics—provide more accurate assessment of biological aging than single-measure approaches. This framework recognizes that individual organs age at different rates, offering a pathway to predict organ-specific disease risk and progression with greater precision.
Longitudinal acceleration in epigenetic clocks—independent of baseline epigenetic age—predicts mortality risk in the InCHIANTI cohort. The rate of change in multiple epigenetic clocks emerges as a more predictive mortality marker than epigenetic age alone, offering refined mortality risk stratification.
Accelerated biological aging measured by the epigenetic clock AgeAccelGrim2 was associated with increased risk of mild cognitive impairment and dementia in 6,069 cognitively unimpaired women over 9.3 years of follow-up, independent of chronological age. This establishes epigenetic markers as measurable indicators of neurodegeneration risk.
Researchers developed scAgeClock, a machine learning model that measures aging at the single-cell level by analyzing gene expression patterns. This cellular-resolution aging clock offers a novel method to detect age-related changes before systemic symptoms emerge, with potential applications in monitoring intervention efficacy and identifying individuals at accelerated aging risk.
